Hydroxyurea therapy in SS children

Research output: Contribution to journalReview articlepeer-review


Children with sickle cell anemia treated with hydroxyurea at 2 years of age maintain Hb F levels above 20% for 4 to 6 years with little hematologic toxicity and no increased risks of infection. Its ability to prevent subclinical organ damage, however, is yet to be proven.

Original languageEnglish (US)
Pages (from-to)2228
Number of pages1
Issue number7
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Hydroxyurea therapy in SS children'. Together they form a unique fingerprint.

Cite this